TY - JOUR T1 - Predicting patient-specific radiotherapy responses in head and neck cancer to personalize radiation dose fractionation JF - bioRxiv DO - 10.1101/630806 SP - 630806 AU - Heiko Enderling AU - Enakshi Sunassee AU - Jimmy J. Caudell Y1 - 2019/01/01 UR - http://biorxiv.org/content/early/2019/05/07/630806.abstract N2 - Human papillomavirus (HPV) related oropharyngeal cancer (OPC) is one of the few types of cancers increasing in incidence. HPV+ OPC treatment with radiotherapy (RT) provides 75-95% five-year locoregional control (LRC). Why some but not all patients with similar clinical stage and molecular profile are controlled remains unknown. We propose the proliferation saturation index, PSI, as a mathematical modeling biomarker of tumor growth and RT response. The model predicts that patients with PSI<0.75 are likely to be cured by radiation, and that hyperfractionated radiation could improve response rates for patients with higher PSI that are predicted to fail standard of care RT. Prospective evaluation is currently ongoing. ER -